RxDoctor Payments Data

Yaron Sternbach, MD

Vascular Surgery · Albany, NYNPI 1205826088

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (41.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Endologix LLC at 29.5% of the total.

$40,026in general payments, 2019–2025

Across 236 payments — averaging $169.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endologix LLC$12K
  • Boston Scientific$9K
  • Abbott$4K
  • W. L. Gore & Associates, Inc.$3K
  • Medtronic$3K
  • Inari Medical, Inc.$2K
  • plus $7K from 19 others
$10,530in research payments, 2019–2025

Across 3 payments — averaging $3510.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Endologix LLC$11K

What the payments were for

  • Consulting fees$16,45041%
  • Speaking & faculty fees$5,10013%
  • Travel & lodging$7,44519%
  • Food & beverage$11,03228%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,026 in reported general payments places this provider in the 85th percentile of 405 vascular surgery providers in New York.

See all vascular surgery providers in New York →

Medicare billing

Part B allowed, 2024
$283,757
Medicare patients
691
Services billed
1,537

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ClopidogrelClopidogrel Bisulfate19$50

Paid to pharmacies, not to this prescriber.

Other vascular surgery in Albany

See the full list for New York →

Where these figures come from

Is this you, or does something look wrong? →